在渐进性超核麻中获得数字健康技术监管批准的途径:范围审查
Catherine Isroff1, Kyurim Kang2, Alberto J Espay3
1Department of Neurology, Mass General Brigham, Boston, MA 02114, USA.
Brain sciences
|June 26, 2025
概括
这次审查发现,对渐进性超核麻 (PSP) 验证数字健康技术 (DHT) 需要标准化指标. 确保DHT捕获以患者为中心的结果对于推进PSP研究和护理至关重要.
科学领域:
- 神经学 神经学
- 数字健康数字健康
- 生物医学工程 生物医学工程
背景情况:
- 渐进性超核麻 (PSP) 是一种神经退行性疾病,具有明显的运动和认知症状.
- 数字健康技术 (DHT) 在临床研究中越来越多地用于结果测量.
- 目前在PSP中DHT的应用缺乏设备和指标的标准化.
研究的目的:
- 进行对已验证的可穿戴式DHTs进行范围审查,以对逐渐超核性麻 (PSP) 进行评估.
- 为了确定PSP的DHT验证的研究差距.
- 概述扩大DHT使用作为主要临床试验终点的步骤.
主要方法:
- 在MEDLINE数据库中进行了系统搜索.
- 审查的重点是使用DHT作为进展性超核麻的结果指标的出版物.
- 鉴定和分析了17个出版物.
主要成果:
- 包括的研究评估了在PSP中测量步态,平衡,上肢功能和语音的DHT.
- 审查发现需要对DHT指标进行一致的验证.
- 目前在PSP研究中的DHT应用具有前景,但需要标准化.
结论:
- 通过严格的验证 (内容,可靠性,构造,响应性,区分有效性) 来标准化DHT指标对于PSP至关重要.
- DHT必须捕捉与现有尺度相比较的临床相关,以患者为中心的结果.
- 将验证的DHT纳入临床试验终点可以加速PSP研究并改善患者护理.
相关概念视频
Psychosurgery
116
Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
116
Parkinson's Disease: Overview
722
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
722
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Preclinical Development: Overview
4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K


